Goodwill Pharma Plc.
- Introduction
- Trading data
- Financials
- Shareholders, management
- Publications
- Product features
| Full Name | Goodwill Pharma Medical and Pharmaceutical Public Limited Company | ||||||
| Short name | Goodwill Pharma Plc. | ||||||
| Sector | Healthcare | ||||||
| Contact |
HU-6724 Szeged, Cserzy M. utca 32.
Phone: +36 62/443-571
Fax: +36 62/423-872
|
||||||
| Investor Relations |
Kristóf József Dr. Szabó
E-mail: szabo.kristof@goodwillpharma.com
Phone: +36 70 657 6211
Fax: +36 62 423 872
|
||||||
| Auditor | CMT Consulting Korlátolt Felelősségű Társaság (auditor: MÓRI Ferencné) | ||||||
| Business activity | Goodwill Pharma is a dynamically growing Hungarian company founded in 1997. The founders, Dr. Ferenc Jójárt and Dr. Mária Kardos, physicians from Szeged, decided to support the health of those in need by developing and distributing high-quality products with curative effects. ^~In the period since then, Goodwill Pharma has been able to grow and innovate continuously, and the Company has become an integrated player with services in many areas of the pharmaceutical industry. ^~The Company s core activities include pharmaceutical logistics and distribution, pharmaceutical registration, full pharmaceutical marketing services, medical promotion, manufacturer and brand representation, own-licensed product development, manufacturing and marketing of proprietary pharmaceuticals and dietary supplements. ^~The first step in the expansion abroad was Serbia, where the Group has had an independent subsidiary for almost 20 years. Goodwill Pharma doo. currently exports to several countries in the Balkans and since 2020 has also had its own pharmaceutical manufacturing capacity. In recent years the Group has established several affiliates in East-Central Europe.^~The Company s primary objective is to become a dominant regional player as a vertically integrated healthcare service provider through the development, manufacturing, distribution and marketing of pharmaceuticals, dietary supplements and medical devices. The Company s extensive pharmaceutical experience and network of contacts, highly skilled human resources and strong financial background provide a solid foundation for this purpose. This development potential is based on the production of internationally competitive products. ^~The Group s brands are characterised by innovation, and its products are developed with a medical eye and pharmaceutical precision, thanks to a highly qualified development team, with the aim of offering complex treatments that can contribute to a cure, a better quality of life or the stabilisation | ||||||
| Listed securities of the issuer |
|
| Basic Information | |
|---|---|
| Ticker | GOODWILLPHRM |
| ISIN | HU0000199575 |
| Date of listing | 25 Apr 2025 |
| Currency of trading | HUF |
| Face Value | 10 HUF |
| Number of securities listed | 107,175,445 |
| Market Capitalisation (HUF million) | 20,363 |
| P/BV | |
|---|---|
| P/BV* | 2.3689 |
* Calculating based on the capitalisation of the actual series only
| Performance | |
|---|---|
* annualized yield
Key annual data
audited, consolidated, Has; Business Year: January 1 - December 31| 20231 | 20241 | |
|---|---|---|
| (thousand HUF) | (thousand HUF) | |
| Total revenues | 14,888,357 | 18,700,610 |
| Operating Profit (EBIT) | 1,488,300 | 2,428,254 |
| Net income from financial activities | 122,359 | -174,799 |
| Profit before tax | 1,610,659 | 2,253,455 |
| Profit after tax | 1,532,120 | 2,155,713 |
| Dividend per (ordinary) share | 5.6 HUF | 5.6 HUF |
| Fixed Assets | 7,755,987 | 11,883,300 |
| Total liabilities | 8,577,167 | 10,201,693 |
| Share capital | 1,071,754 | 1,071,764 |
| Shareholders equity | 7,126,429 | 8,595,976 |
| Total assets | 18,333,761 | 21,260,841 |
| Number of employees (at business year end) | 245 | 277 |
- (1) audited, consolidated, Has; Business Year: January 1 - December 31
Selected financial ratios
Ratios are based on data submitted by the company| 2023 | 2024 | |
|---|---|---|
| Equity Ratio | 1.2 | 1.19 |
| Return on assets (ROA) | 0.21 | 0.25 |
| Return on equity (ROE) | 0.08 | 0.1 |
Mid-year reports
non-audited, consolidated, in compliance with has; Business Year: January 1 - June 30| Key P&L Figures | Jan 2023 - Jun 20231 | Jan 2024 - Jun 20241 |
|---|---|---|
| (thousand HUF) | (thousand HUF) | |
| Net sales | 7,105,631 | 8,583,389 |
| Operating profit (EBIT) | 747,423 | 1,099,804 |
| Net income from financial activities | 96,747 | -26,379 |
| Profit before tax | 844,170 | 1,073,425 |
| Profit after tax | 819,834 | 1,033,055 |
| Key Balance Sheet Items | 30 Jun 2023 | 30 Jun 2024 |
|---|---|---|
| (thousand HUF) | (thousand HUF) | |
| Fixed Assets | 6,687,192 | 10,225,283 |
| Intangible Assets | 675,173 | 690,568 |
| Tangible assets | 5,998,892 | 9,520,666 |
| Invested financial assets | 13,127 | 14,048 |
| Current Assets | 8,204,112 | 9,360,543 |
| Inventory | 3,863,518 | 4,740,214 |
| Total assets | 15,166,001 | 19,867,282 |
| Shareholders equity | 5,181,750 | 7,492,395 |
| Share capital | 1,001,579 | 1,071,764 |
| Long-term liabilities | 3,948,907 | 4,938,036 |
| Short-term liabilities | 2,726,132 | 4,021,557 |
| Total liabilities and shareholders equity | 15,166,001 | 19,867,282 |
- (1) non-audited, consolidated, in compliance with has; Business Year: January 1 - June 30
| Shareholders exceeding 5% stake with respect to the listed series | ||
|---|---|---|
| Name | Shareholding (%) | Share piece |
| Dr. Ferenc JÓJÁRT | 71.10 | 76,197,369 |
| Dr. Mária JÓJÁRTNÉ KARDOS | 22.45 | 24,065,789 |
| Free Float: 6.45% | Last update: 28 Feb 2025 | |
| Note: When determining the Free Float for a particular series, all the securities of the company shall be regarded to be publicly held other than (i) the stock of securities held by holders with direct holdings of more than 5% of the total number of securities, (ii) securities in the possession of custodians, provided the certificate available to the custodian verifies that the particular person holds more than 5% of the total number of securities outstanding belonging to the series. The value of the free float is based on the data provided by the issuer. | ||
| Management | |
|---|---|
| Management Board | Dr. Ferenc JÓJÁRT (chairman), Dr. Mária KARDOS JÓJÁRTNÉ , Gábor BAJÚSZ, Csaba RÁCZ |
| Management | Dr. Ferenc JÓJÁRT (CEO), Dr. Mária JÓJÁRTNÉ KARDOS (marketing director), Gábor BAJÚSZ (CEO) Csaba RÁCZ (CFO) |
| Supervisory Board | Péter VITKOVICS, Zsolt HORVÁTH, István LUKÁCSI, János KŐVÁGÓ |
| Last update: 29 May 2025 | |
Note: Publications of this issuer are available in Hungarian only.
| Publication | News |
|---|---|
| 06 Jun 2025 13:56 | Alapszabály |
| 06 Jun 2025 13:53 | Osztalékfizetés |
| 30 May 2025 14:15 | Szavazati jogok, alaptőke |
| 27 May 2025 15:49 | Rendkívüli tájékoztatás |
| 27 May 2025 11:54 | Alapszabály |
| 27 May 2025 11:43 | Éves Jelentés |
| 27 May 2025 09:55 | Közgyűlési határozatok |
| 15 May 2025 13:45 | Rendkívüli tájékoztatás |
| 30 Apr 2025 17:06 | Közgyűlési előterjesztések |
| 30 Apr 2025 09:16 | Szavazati jogok, alaptőke |
| Publication | Report |
|---|---|
| 27 May 2025 11:43 | Éves Jelentés |
| 18 Sep 2024 15:26 | Goodwill Csoport tőzsdei jelentés 2024. I. félév |
| Publication | Articles of Association |
|---|---|
| 06 Jun 2025 13:56 | Alapszabály |
| Publication | Voting rights, registered capital |
|---|---|
| 30 May 2025 14:15 | Szavazati jogok, alaptőke |
| Name of security | Goodwill Pharma Nyrt. ordinary share |
| Issuer | Goodwill Pharma Medical and Pharmaceutical Public Limited Company |
| Equity class | Ordinary share |
| Type of security | Registered |
| Form of security | Dematerialised |
| Code of security (ISIN) | HU0000199575 |
| Ticker symbol | GOODWILLPHRM |
| Face value | 10 HUF |
| Number of securities listed | 107,175,445 |
| Rights to dividends | Full year |
| Listing date | 25 Apr 2025 |
| First Trading Day | 25 Apr 2025 |
| Market | Standard |
| Trading Unit | |
| Currency of trading | HUF |
| Trading time | |
| Listing price | 190 |